US: +1 646-781-8004 | Europe:+44-203-868-8738 | APAC:+91-744-778-0008

Real World Evidence Solutions Market

Release date:

Nov-2021

Region:

global

Research Code:MRHC - 104253

Sku:MRHC - 104253

Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2028

  • Report ID: MRHC - 104253
  • Pages: 214
  • Nov-2021
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 2 to 4 Hours
COVID-19

This report provides pre & post COVID-19 market estimates.

The RWE Solutions Market is expected to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028. Real-world evidence (RWE) is clinical evidence gathered via Real-Word data (RWD) analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are expected to positively impact the RWE solutions market.

Impact of COVID-19 on RWE Solutions Market

The key players operating in the RWE solutions market experienced an initial market shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting of resources on COVID-19 treatments in healthcare settings, and limited access to hospitals.

 However, after the initial market shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology to combat the COVID-19 outbreak.

Healthcare professionals are working tirelessly on faster diagnosis, rapid response, and effective use of human resources and ensuring the safety of medical personnel all over the globe. As the COVID-19 outbreak continues to take its toll on global markets, real-world evidence (RWE) is set to become the most influential emerging technology to combat the COVID-19 outbreak. Real-world evidence is becoming an essential tool in trying to suppress COVID-19. There are growing interests in whether non-randomized real-world evidence (RWE) can be used to supplement RCT evidence and aid in clinical decision-making, but concerns about non-randomized RWE have been highlighted by a proliferation of RWE studies on medications and COVID-19 outcomes with widely varying conclusions. A systematic approach to generating information to support clinical and public health decision-making is needed. Real-world data (RWD) captured directly from patients or through medical claims or electronic medical records (EMRs), has the potential to support clinical decision-making.

Real World Evidence Solutions Market

                                                  Click here to: Get Free Request Sample Copy of this report

Key Findings in the Global RWE Solutions Market Study

Datasets Generated Larger Proportion of Revenue Compared to Consulting Services

The datasets segment is estimated to account for a larger share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Market access & reimbursement/coverage decisions to Dominate the Market.

The market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing demand for real-world data and real-world evidence for accelerating market access & reimbursement/coverage decisions, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).

Pharmaceutical, Biotechnology, & Medical Device Companies Segment to Register Largest Share in the RWE solutions market by 2028.

The pharmaceutical, biotechnology, & medical device companies segment is estimated to account for the largest share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

Asia-Pacific: Fastest Growing Regional Market

North America is estimated to command the largest share of the global RWE solutions market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa.

However, Asia-Pacific is expected to be the fastest-growing regional market due to growing demand from payers for data that defines the value and effectiveness of medicines, growing demand in conducting real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years. The key players profiled in the global RWE solutions market report includes IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.) , CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report

RWE Solutions Market, by Component

  • Datasets
    • Disparate Datasets
      • EMR/EHR/Clinical Data
      • Claims & Billing Data
      • Pharmacy Data
      • Product/Disease Registries Data
      • Other Disparate Datasets
    • Integrated Datasets
  • Consulting & Analytics

(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

RWE Solutions Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
    • Oncology
    • Neurology
    • Immunology
    • Cardiovascular Diseases
    • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications
    (Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)

RWE Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users 
    (Note: Other end-users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

RWE Solutions Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Singapore
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report:

What is the focus of the global RWE solutions market?

The global RWE solutions market covers the market sizes & forecasts the various real-world evidence solutions offered by key market players to support pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to market access and reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals. The RWE solutions market studied in this report involves the value analysis of various segments and subsegments of RWE solutions providers at the regional and country levels.

What is the value of revenue generated from the RWE solutions across the globe? at what rate is their demand expected to grow for the next 5–7 years?

The global RWE solutions market is projected to reach $4.4 billion by 2028, at a CAGR of 11.8% during the forecast period.

Which component type is estimated to hold the major share of the market?

Based on component, the datasets segment is estimated to account for the largest share of the RWE solutions market in 2020. The large market share of this segment is mainly attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Which application segment of the market is projected to create more traction in the RWE solutions market?

The drug development & approvals segment is estimated to register the fastest CAGR during the forecast period due to increasing demand for real-world data and real-world evidence for accelerating drug discovery and development, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).

What are the key factors supporting the growth of this market? also, what are the major opportunities for existing market players and new entrants in the global RWE solutions market?

Growing incidence of chronic diseases, delays in drug development, and the subsequent increase in development costs, rapidly growing big data in healthcare, shift from volume to value-based care, and the rising focus towards personalized healthcare are expected to positively impact the growth of the RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to-end RWE services, and the rising adoption of wearable devices and AI in RWE.

Who are the major players operating in the global RWE solutions market?

Key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Which regions/countries are expected to offer significant growth opportunities for the companies operating in the RWE solutions market?

Emerging economies from the Asian region such as Japan and China are projected to offer significant growth opportunities for the companies in operating this market. The growing demand from payers for data that defines the value and effectiveness of medicines, growing demand in conducting real-world studies in drug R&D, and the increasing government interest in using real-world studies for regulatory decision-making are the factors expected to offer significant growth opportunities in this region.

1.    Introduction
        1.1.    Market Definition 
        1.2.    Market Ecosystem 
        1.3.    Currency 

2.    Research Methodology 
        2.1.    Research Process 
        2.2.    Data Collection & Validation 
                  2.2.1.    Secondary Research 
                  2.2.2.    Primary Research 
        2.3.    Market Assessment 
                  2.3.1.    Market Size Estimation 
                               2.3.1.1.    Bottom-Up Approach 

3.    Executive Summary 

4.    Market Insights 
        4.1.    Market Overview 
        4.2.    Drivers 
                  4.2.1.    Growing Burden of Chronic Diseases 
                  4.2.2.    Rising Focus Towards Personalized Healthcare 
                  4.2.3.    Delays in Drug Development and the Subsequent Increase in Development Costs 
                  4.2.4.    Shift Towards Value-Based Care 
                  4.2.5.    Rapidly Growing Big Data in Healthcare 
        4.3.    Restraints 
                  4.3.1.    Reluctance to Rely on Real-World Studies 
        4.4.    Opportunities 
                  4.4.1.    Emerging Economies 
                  4.4.2.    Rising Focus on End-To-End RWE Services 
                  4.4.3.    Rising Adoption of Wearable Devices and Artificial Intelligence in RWE 
        4.5.    Challenges 
                  4.5.1.    Lack of Standardized Methodologies to Develop RWE 
        4.6.    Impact Assessment of COVID-19 
        4.7.    Key Market Trends 
                  4.7.1.    Growing Adoption of RWE in Drug Development and Commercialization 
                  4.7.2.    Rising Number of Consolidations 
                  4.7.3.    Improved Patient Outcomes and value Creation from real world Evidence 

5.    Regulatory Analysis – Real-World Evidence (RWE) Solutions Market 
        5.1.    Introduction 
        5.2.    North America 
        5.3.    Europe 
        5.4.    Asia-Pacific 
        5.5.    Rest of the World 

6.    Pricing Models (Emr/Genomic/Integrated Datasets) 
        6.1.    Introduction 
        6.2.    Pay Per Patient Record (Volume-Based Pricing) 
        6.3.    Pay Per Usage (Value-Based Pricing) 
        6.4.    Annual Subscription 

7.    Global Real-World Evidence Solutions Market, by Component 
        7.1.    Introduction 
        7.2.    Datasets 
                  7.2.1.   Disparate Datasets 
                               7.2.1.1.    EMR/EHR/Clinical Data 
                               7.2.1.2.    Claims & Billing Data 
                               7.2.1.3.    Pharmacy Data 
                               7.2.1.4.    Product/Disease Registries Data 
                               7.2.1.5.    Other Disparate Datasets 
                  7.2.2.    Integrated Datasets 
        7.3.    Consulting & Analytics 

8.    Global Real-World Evidence Solutions Market, by Application 
        8.1.    Introduction 
        8.2.    Market Access & Reimbursement/Coverage Decisions 
        8.3.    Drug Development & Approvals 
                  8.3.1.    Oncology 
                  8.3.2.    Neurology 
                  8.3.3.    Immunology 
                  8.3.4.    Cardiovascular Diseases 
                  8.3.5.    Other Therapeutic Areas 
        8.4.    Post Market Surveillance 
        8.5.     Medical Device Development & Approvals
        8.6.    Other Applications 

9.    Global Real-World Evidence Solutions Market, by End User 
        9.1.    Introduction 
        9.2.    Pharmaceutical, Biotechnology, and Medical Device Companies 
        9.3.    Healthcare Payers 
        9.4.    Healthcare Providers 
        9.5.    Other End Users 

10.    Global Real-World Evidence Solutions Market, by Geography 
         10.1.    Introduction 
         10.2.    North America 
                     10.2.1.    U.S. 
                     10.2.2.    Canada 
         10.3.    Europe 
                     10.3.1.    U.K. 
                     10.3.2.    Germany 
                     10.3.3.    France 
                     10.3.4.    Italy
                     10.3.5.    Spain
                     10.3.6.    Rest of Europe
         10.4.    Asia-Pacific
                     10.4.1.    Japan 
                     10.4.2.    China 
                     10.4.3.    India 
                     10.4.4.    South Korea 
                     10.4.5.    Taiwan 
                     10.4.6.    Singapore 
                     10.4.7.    Rest of Asia-Pacific 
         10.5.    Latin America 
         10.6.    Middle East & Africa 

11.    Competitive Landscape 
         11.1.    Introduction 
         11.2.    Key Growth Strategies 
         11.3.    Competitive Benchmarking 
         11.4.    Market Share Analysis (2020) 
                     11.4.1.    IQVIA Holdings, Inc. (U.S.) 
                     11.4.2.    Icon Plc (Ireland) 
                     11.4.3.    PPD, Inc. 

12.    Company Profiles 
         12.1.    IQVIA Holdings Inc. 
                     12.1.1.    Business Overview 
                     12.1.2.    Financial Overview 
                     12.1.3.    Product Portfolio 
                     12.1.4.    Strategic Developments 
         12.2.    PPD, Inc. 
                     12.2.1.    Business Overview 
                     12.2.2.    Financial Overview 
                     12.2.3.    Product Portfolio 
                     12.2.4.    Strategic Developments 
         12.3.    ICON plc 
                     12.3.1.    Business Overview 
                     12.3.2.    Financial Overview 
                     12.3.3.    Product Portfolio 
                     12.3.4.    Strategic Developments 
         12.4.    SYNEOS HEALTH, INC.
                     12.4.1.    Business Overview 
                     12.4.2.    Financial Overview 
                     12.4.3.    Product Portfolio 
                     12.4.4.    Strategic Developments 
         12.5.    CLARIVATE PLC
                     12.5.1.    Business Overview 
                     12.5.2.    Financial Overview 
                     12.5.3.    Product Portfolio 
         12.6.    Medpace Holdings Inc.
                     12.6.1.    Business Overview 
                     12.6.2.    Financial Overview 
                     12.6.3.    Product Portfolio 
         12.7.    Symphony Innovation, LLC
                     12.7.1.    Business Overview 
                     12.7.2.    Product Portfolio 
                     12.7.3.    Strategic Developments 
         12.8.    PAREXEL International Corporation 
                     12.8.1.    Business Overview 
                     12.8.2.    Product Portfolio 
                     12.8.3.    Strategic Developments 
         12.9.    IBM Corporation 
                     12.9.1.    Business Overview
                     12.9.2.    Financial Overview 
                     12.9.3.    Product Portfolio 
                     12.9.4.    Strategic Developments 
         12.10.  UnitedHealth Group Incorporated 
                     12.10.1.    Business Overview 
                     12.10.2.    Financial Overview 
                     12.10.3.    Product Portfolio 
         12.11.  Flatiron Health 
                     12.11.1.    Business Overview 
                     12.11.2.    Product Portfolio 
                     12.11.3.    Strategic Developments 
         12.12.  Oracle Corporation 
                     12.12.1.    Business Overview 
                     12.12.2.    Financial Overview 
                     12.12.3.    Product Portfolio 
         12.13.  SAS Institute, Inc. 
                     12.13.1.    Business Overview 
                     12.13.2.    Product Portfolio 
                     12.13.2.    Strategic Developments 
         12.14.  Clinigen Group plc 
                     12.14.1.    Business Overview 
                     12.14.2.    Financial Overview 
                     12.14.3.    Product Portfolio 
         12.15.  Cognizant Technology Solutions Corporation 
                     12.15.1.    Business Overview 
                     12.15.2.    Financial Overview 
                     12.15.3.    Product Portfolio 
         12.16.  PerkinElmer, Inc. 
                     12.16.1.    Business Overview 
                     12.16.2.    Financial Overview 
                     12.16.3.    Product Portfolio 

13.    Appendix 
         13.1.    Questionnaire 
         13.2.    Available Customization 

List of Tables

Table 1    Global Real-World Evidencesolutions Market Drivers: Impact Analysis (2021-2028)
Table 2    Number of Persons Aged 65 Years or Over, by Region, (2019 Vs. 2050)
Table 3    Total Per-Study Cost (In USD Million), by Phase and Therapeutic Area
Table 4    Sources of Healthcare Data
Table 5    Global Real-World Evidence Solutions Market Restraints: Impact Analysis (2021-2028)
Table 6    RWE in Latin American Countries
Table 7    Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 8    Global Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 9    Global Real-World Evidence Solutions Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 10    Real-World Evidence Solutions Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 11    Global RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 12    RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 13    RWE Emr/Ehr/Clinical Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 14    RWE Claims & Billing Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 15    RWE Pharmacy Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 16    RWE Product/Disease Registries Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 17    Other RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 18    RWE Integrated Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 19    RWE Consulting & Analytics Market Size, by Country/Region, 2019–2028 (USD Million)
Table 20    Global Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 21    Global RWE Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2028 (USD Million)
Table 22    Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 23    Global RWE Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 24    Oncology: Drugs in the R&D Pipeline
Table 25    Global RWE Solutions Market Size for Oncology, by Country/Region, 2019–2028 (USD Million)
Table 26    Neurology: Drugs in the R&D Pipeline
Table 27    Global RWE Solutions Market Size for Neurology, by Country/Region, 2019–2028 (USD Million)
Table 28    Immunology: Drugs in the R&D Pipeline
Table 29    Global RWE Solutions Market Size for Immunology, by Country/Region, 2019–2028 (USD Million)
Table 30    Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 31    Cardiovascular Diseases: Drugs in the R&D Pipeline
Table 32    Global RWE Solutions Market Size for Cardiovascular Diseases, by Country/Region, 2019–2028 (USD Million)
Table 33    Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 34    Global RWE Solutions Market Size for Other Therapeutic Areas, by Country/Region, 2019–2028 (USD Million)
Table 35    Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 36    Global RWE Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2028 (USD Million)
Table 37    Global RWE Solutions Market Size for Other Applications,  by Country/Region, 2019–2028 (USD Million)
Table 38    Global RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 39   Global RWE Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2019–2028 (USD Million)
Table 40    Global RWE Solutions Market Size for Healthcare Payers, by Country/Region, 2019–2028 (USD Million)
Table 41    Global RWE Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2028 (USD Million)
Table 42    Global RWE Solutions Market Size for Other End Users,  by Country/Region, 2019–2028 (USD Million)
Table 43    Global Real-World Evidence Solutions Market, by Country/Region, 2019–2028 (USD Million)
Table 44    North America: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 45    North America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 46    North America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 47    North America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 48    North America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 49    North America: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 50    North America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 51    U.S.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 52    U.S.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 53    U.S.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 54    U.S.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 55    U.S.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 56    U.S.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 57    Number of Active Clinical Trials in Canada, by Condition, 2019
Table 58    Canada: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 59    Canada: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 60    Canada: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 61    Canada: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 62    Canada: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 63    Canada: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 64    Europe: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 65    Europe: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 66    Europe: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 67    Europe: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 68    Europe: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 69    Europe: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 70    Europe: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 71    U.K.: Conferences and Workshops on Real-World Evidence Solutions
Table 72    U.K.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 73    U.K.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 74    U.K.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 75    U.K.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 76    U.K.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 77    U.K.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 78    Conferences, Symposia, and Workshops in Germany
Table 79    Germany: Real-World Evidence Solutions Market Size, by Component,  2019–2028 (USD Million)
Table 80    Germany: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 81    Germany: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 82    Germany: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 83    Germany: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 84    Germany: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 85    France: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 86    France: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 87    France: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 88    France: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 89    France: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 90    France: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 91    Italy: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 92    Italy: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 93    Italy: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 94    Italy: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 95    Italy: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 96    Italy: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 97    Spain: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 98    Spain: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 99    Spain: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 100    Spain: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 101    Spain: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 102    Spain: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 103    RoE: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 104    RoE: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 105    RoE: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 106    RoE: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 107    RoE: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 108    RoE: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 109    Asia-Pacific: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 110    Asia-Pacific: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 111    Asia-Pacific: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 112    Asia-Pacific: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 113    Asia-Pacific: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 114    Asia-Pacific: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 115    Asia-Pacific: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 116    Japan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 117    Japan: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 118    Japan: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 119    Japan: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 120    Japan: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 121    Japan: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 122    Diversified Real-World Data Sources in China
Table 123    China: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 124    China: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 125    China: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 126    China: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 127    China: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 128    China: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 135    South Korea: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 141    RWE Sources Of Taiwan
Table 142    Taiwan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 148    Singapore: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 154    Estimated Number of New Cancer Cases From 2020 to 2030
Table 155    RoAPAC: Real-World Evidence Solutions Market Size, by Component,  2019–2028 (USD Million)
Table 156    RoAPAC: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 157    RoAPAC: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 158    RoAPAC: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 159    RoAPAC: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 160    RoAPAC: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 161    Latin America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 162    Latin America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 163    Latin America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 164    Latin America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 165    Latin America: RWE Market Size for Drug Development & Approvals,  by Therapeutic Area, 2019–2028 (USD Million)
Table 166    Latin America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 167    Middle East & Africa: Real-World Evidence Solutions Market Size,  by Component, 2019–2028 (USD Million)
Table 168    Middle East & Africa: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 169    Middle East & Africa: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 170    Middle East & Africa: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 171    Middle East & Africa: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 172    Middle East & Africa: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 173    Recent Developments, by Company, 2018–2021 

List of Figures

Figure 1    Key Stakeholders 
Figure 2    Research Process 
Figure 3    Key Secondary Sources 
Figure 4    Primary Research Techniques 
Figure 5    Key Executives Interviewed 
Figure 6    Breakdown of Primary Interviews (Supply-Side & Demand-Side) 
Figure 7    Market Size Estimation 
Figure 8    Global Real-World Evidence Solutions Market, by Component, 2021 Vs. 2028 (USD Million) 
Figure 9    Global Real-World Evidence Solutions Market, by Application, 2021 Vs. 2028 (USD Million) 
Figure 10    Global Real-World Evidence Solutions Market, by End User, 2021 Vs. 2028 (USD Million) 
Figure 11    Real-World Evidence Solutions Market, by Geography 
Figure 12    Market Dynamics 
Figure 13    Number of People With Chronic Conditions in the U.S. (2000–2030) 
Figure 14    Percentage of Personalized Medicines Approved (2015–2020) 
Figure 15    Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012–2020) 
Figure 16    Global Real-World Evidence Solutions Market Size, by Component, 2021–2028 (USD Million) 
Figure 17    U.S.: Number of E-Prescriptions, 2013–2020 (Billions) 
Figure 18    Global Real-World Evidence Solutions Market Size, by Application, 2021–2028(USD Million) 
Figure 19    Estimated Number of New Cancer Cases, by Region, 2020–2040 (in Millions) 
Figure 20    Global Real-World Evidence Solutions Market Size, by End User, 2021–2028 (USD Million) 
Figure 21    Pharmaceutical R&D Spending, 2012–2026 (USD Billion) 
Figure 22    Global Real-World Evidence Solutions Market, by Region, 2021–2028 (USD Million) 
Figure 23    North America: Real-World Evidence Solutions Market Snapshot 
Figure 24    Number of Novel Drug Approvals by CDER in a Year, 2010–2020 
Figure 25    Europe: Real-World Evidence Solutions Market Snapshot 
Figure 26    Pharmaceutical Industry R&D Expenditure in Germany, 2016–2019 (USD Million) 
Figure 27    France: Share of Population Aged 65 & Above, 2010–2020 
Figure 28    Italy: Share of Population Aged 65 Years and Above, 2015–2020 
Figure 29    Pharmaceutical R&D Expenditure in Spain, 2016–2019 (USD Million) 
Figure 30    Pharmaceutical R&D Expenditure in European Countries, 2016–2019 (USD Million) 
Figure 31    Asia-Pacific: Real-World Evidence Solutions Market Snapshot 
Figure 32    Number of People >65 Years of Age in Japan, 2000–2050 
Figure 33    Key Growth Strategies Adopted by Leading Players (2018–2021) 
Figure 34    Real-World Evidence Solutions: Competitive Benchmarking 
Figure 35    Market Share Analysis: Real-World Evidence Solutions Industry (2020) 
Figure 36    IQVIA Holdings Inc.: Financial Overview, 2020 
Figure 37    PPD, Inc.: Financial Overview, 2020 
Figure 38    ICON plc: Financial Overview, 2020 
Figure 39    SYNEOS HEALTH, INC.: financial overview (2020)
Figure 40    CLARIVATE PLC: financial overview (2020)
Figure 41    Medpace Holdings, Inc.: financial overview, 2020
Figure 42    IBM Corporation: Financial Overview, 2020 
Figure 43    UnitedHealth Group Incorporated: Financial Overview, 2020 
Figure 44    Oracle Corporation: Financial Overview, 2021 
Figure 45    Clinigen Group plc: Financial Overview, 2021 
Figure 46    Cognizant Technology Solutions Corporation: Financial Overview, 2020 
Figure 47    PerkinElmer, Inc.: Financial Overview, 2020 

 
Name can only consist of alphabets.
Please provide your full name.
 
Please provide valid email address.
Please provide your email address.
 
Please provide your job title.
 
Please provide your company name.
 
Please provide your company name.
 
Please provide valid phone number.
Please provide your phone number.
 
Please enter minimum 10 characters.
 
Please enter Captcha.
Please enter valid Captcha.

This website is secure and we do not share your personal information with any third party. Privacy Policy

Related Research

The RWE Solutions Market is expected to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028. Real-world evidence (RWE) is clinical evidence gathered via Real-Word data (RWD) analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are expected to positively impact the RWE solutions market.

Impact of COVID-19 on RWE Solutions Market

The key players operating in the RWE solutions market experienced an initial market shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting of resources on COVID-19 treatments in healthcare settings, and limited access to hospitals.

 However, after the initial market shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology to combat the COVID-19 outbreak.

Healthcare professionals are working tirelessly on faster diagnosis, rapid response, and effective use of human resources and ensuring the safety of medical personnel all over the globe. As the COVID-19 outbreak continues to take its toll on global markets, real-world evidence (RWE) is set to become the most influential emerging technology to combat the COVID-19 outbreak. Real-world evidence is becoming an essential tool in trying to suppress COVID-19. There are growing interests in whether non-randomized real-world evidence (RWE) can be used to supplement RCT evidence and aid in clinical decision-making, but concerns about non-randomized RWE have been highlighted by a proliferation of RWE studies on medications and COVID-19 outcomes with widely varying conclusions. A systematic approach to generating information to support clinical and public health decision-making is needed. Real-world data (RWD) captured directly from patients or through medical claims or electronic medical records (EMRs), has the potential to support clinical decision-making.

Real World Evidence Solutions Market

                                                  Click here to: Get Free Request Sample Copy of this report

Key Findings in the Global RWE Solutions Market Study

Datasets Generated Larger Proportion of Revenue Compared to Consulting Services

The datasets segment is estimated to account for a larger share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Market access & reimbursement/coverage decisions to Dominate the Market.

The market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing demand for real-world data and real-world evidence for accelerating market access & reimbursement/coverage decisions, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).

Pharmaceutical, Biotechnology, & Medical Device Companies Segment to Register Largest Share in the RWE solutions market by 2028.

The pharmaceutical, biotechnology, & medical device companies segment is estimated to account for the largest share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

Asia-Pacific: Fastest Growing Regional Market

North America is estimated to command the largest share of the global RWE solutions market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa.

However, Asia-Pacific is expected to be the fastest-growing regional market due to growing demand from payers for data that defines the value and effectiveness of medicines, growing demand in conducting real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years. The key players profiled in the global RWE solutions market report includes IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.) , CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report

RWE Solutions Market, by Component

  • Datasets
    • Disparate Datasets
      • EMR/EHR/Clinical Data
      • Claims & Billing Data
      • Pharmacy Data
      • Product/Disease Registries Data
      • Other Disparate Datasets
    • Integrated Datasets
  • Consulting & Analytics

(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

RWE Solutions Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
    • Oncology
    • Neurology
    • Immunology
    • Cardiovascular Diseases
    • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications
    (Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)

RWE Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users 
    (Note: Other end-users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

RWE Solutions Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Singapore
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report:

  Request Sample

1.    Introduction
        1.1.    Market Definition 
        1.2.    Market Ecosystem 
        1.3.    Currency 

2.    Research Methodology 
        2.1.    Research Process 
        2.2.    Data Collection & Validation 
                  2.2.1.    Secondary Research 
                  2.2.2.    Primary Research 
        2.3.    Market Assessment 
                  2.3.1.    Market Size Estimation 
                               2.3.1.1.    Bottom-Up Approach 

3.    Executive Summary 

4.    Market Insights 
        4.1.    Market Overview 
        4.2.    Drivers 
                  4.2.1.    Growing Burden of Chronic Diseases 
                  4.2.2.    Rising Focus Towards Personalized Healthcare 
                  4.2.3.    Delays in Drug Development and the Subsequent Increase in Development Costs 
                  4.2.4.    Shift Towards Value-Based Care 
                  4.2.5.    Rapidly Growing Big Data in Healthcare 
        4.3.    Restraints 
                  4.3.1.    Reluctance to Rely on Real-World Studies 
        4.4.    Opportunities 
                  4.4.1.    Emerging Economies 
                  4.4.2.    Rising Focus on End-To-End RWE Services 
                  4.4.3.    Rising Adoption of Wearable Devices and Artificial Intelligence in RWE 
        4.5.    Challenges 
                  4.5.1.    Lack of Standardized Methodologies to Develop RWE 
        4.6.    Impact Assessment of COVID-19 
        4.7.    Key Market Trends 
                  4.7.1.    Growing Adoption of RWE in Drug Development and Commercialization 
                  4.7.2.    Rising Number of Consolidations 
                  4.7.3.    Improved Patient Outcomes and value Creation from real world Evidence 

5.    Regulatory Analysis – Real-World Evidence (RWE) Solutions Market 
        5.1.    Introduction 
        5.2.    North America 
        5.3.    Europe 
        5.4.    Asia-Pacific 
        5.5.    Rest of the World 

6.    Pricing Models (Emr/Genomic/Integrated Datasets) 
        6.1.    Introduction 
        6.2.    Pay Per Patient Record (Volume-Based Pricing) 
        6.3.    Pay Per Usage (Value-Based Pricing) 
        6.4.    Annual Subscription 

7.    Global Real-World Evidence Solutions Market, by Component 
        7.1.    Introduction 
        7.2.    Datasets 
                  7.2.1.   Disparate Datasets 
                               7.2.1.1.    EMR/EHR/Clinical Data 
                               7.2.1.2.    Claims & Billing Data 
                               7.2.1.3.    Pharmacy Data 
                               7.2.1.4.    Product/Disease Registries Data 
                               7.2.1.5.    Other Disparate Datasets 
                  7.2.2.    Integrated Datasets 
        7.3.    Consulting & Analytics 

8.    Global Real-World Evidence Solutions Market, by Application 
        8.1.    Introduction 
        8.2.    Market Access & Reimbursement/Coverage Decisions 
        8.3.    Drug Development & Approvals 
                  8.3.1.    Oncology 
                  8.3.2.    Neurology 
                  8.3.3.    Immunology 
                  8.3.4.    Cardiovascular Diseases 
                  8.3.5.    Other Therapeutic Areas 
        8.4.    Post Market Surveillance 
        8.5.     Medical Device Development & Approvals
        8.6.    Other Applications 

9.    Global Real-World Evidence Solutions Market, by End User 
        9.1.    Introduction 
        9.2.    Pharmaceutical, Biotechnology, and Medical Device Companies 
        9.3.    Healthcare Payers 
        9.4.    Healthcare Providers 
        9.5.    Other End Users 

10.    Global Real-World Evidence Solutions Market, by Geography 
         10.1.    Introduction 
         10.2.    North America 
                     10.2.1.    U.S. 
                     10.2.2.    Canada 
         10.3.    Europe 
                     10.3.1.    U.K. 
                     10.3.2.    Germany 
                     10.3.3.    France 
                     10.3.4.    Italy
                     10.3.5.    Spain
                     10.3.6.    Rest of Europe
         10.4.    Asia-Pacific
                     10.4.1.    Japan 
                     10.4.2.    China 
                     10.4.3.    India 
                     10.4.4.    South Korea 
                     10.4.5.    Taiwan 
                     10.4.6.    Singapore 
                     10.4.7.    Rest of Asia-Pacific 
         10.5.    Latin America 
         10.6.    Middle East & Africa 

11.    Competitive Landscape 
         11.1.    Introduction 
         11.2.    Key Growth Strategies 
         11.3.    Competitive Benchmarking 
         11.4.    Market Share Analysis (2020) 
                     11.4.1.    IQVIA Holdings, Inc. (U.S.) 
                     11.4.2.    Icon Plc (Ireland) 
                     11.4.3.    PPD, Inc. 

12.    Company Profiles 
         12.1.    IQVIA Holdings Inc. 
                     12.1.1.    Business Overview 
                     12.1.2.    Financial Overview 
                     12.1.3.    Product Portfolio 
                     12.1.4.    Strategic Developments 
         12.2.    PPD, Inc. 
                     12.2.1.    Business Overview 
                     12.2.2.    Financial Overview 
                     12.2.3.    Product Portfolio 
                     12.2.4.    Strategic Developments 
         12.3.    ICON plc 
                     12.3.1.    Business Overview 
                     12.3.2.    Financial Overview 
                     12.3.3.    Product Portfolio 
                     12.3.4.    Strategic Developments 
         12.4.    SYNEOS HEALTH, INC.
                     12.4.1.    Business Overview 
                     12.4.2.    Financial Overview 
                     12.4.3.    Product Portfolio 
                     12.4.4.    Strategic Developments 
         12.5.    CLARIVATE PLC
                     12.5.1.    Business Overview 
                     12.5.2.    Financial Overview 
                     12.5.3.    Product Portfolio 
         12.6.    Medpace Holdings Inc.
                     12.6.1.    Business Overview 
                     12.6.2.    Financial Overview 
                     12.6.3.    Product Portfolio 
         12.7.    Symphony Innovation, LLC
                     12.7.1.    Business Overview 
                     12.7.2.    Product Portfolio 
                     12.7.3.    Strategic Developments 
         12.8.    PAREXEL International Corporation 
                     12.8.1.    Business Overview 
                     12.8.2.    Product Portfolio 
                     12.8.3.    Strategic Developments 
         12.9.    IBM Corporation 
                     12.9.1.    Business Overview
                     12.9.2.    Financial Overview 
                     12.9.3.    Product Portfolio 
                     12.9.4.    Strategic Developments 
         12.10.  UnitedHealth Group Incorporated 
                     12.10.1.    Business Overview 
                     12.10.2.    Financial Overview 
                     12.10.3.    Product Portfolio 
         12.11.  Flatiron Health 
                     12.11.1.    Business Overview 
                     12.11.2.    Product Portfolio 
                     12.11.3.    Strategic Developments 
         12.12.  Oracle Corporation 
                     12.12.1.    Business Overview 
                     12.12.2.    Financial Overview 
                     12.12.3.    Product Portfolio 
         12.13.  SAS Institute, Inc. 
                     12.13.1.    Business Overview 
                     12.13.2.    Product Portfolio 
                     12.13.2.    Strategic Developments 
         12.14.  Clinigen Group plc 
                     12.14.1.    Business Overview 
                     12.14.2.    Financial Overview 
                     12.14.3.    Product Portfolio 
         12.15.  Cognizant Technology Solutions Corporation 
                     12.15.1.    Business Overview 
                     12.15.2.    Financial Overview 
                     12.15.3.    Product Portfolio 
         12.16.  PerkinElmer, Inc. 
                     12.16.1.    Business Overview 
                     12.16.2.    Financial Overview 
                     12.16.3.    Product Portfolio 

13.    Appendix 
         13.1.    Questionnaire 
         13.2.    Available Customization 

List of Tables

Table 1    Global Real-World Evidencesolutions Market Drivers: Impact Analysis (2021-2028)
Table 2    Number of Persons Aged 65 Years or Over, by Region, (2019 Vs. 2050)
Table 3    Total Per-Study Cost (In USD Million), by Phase and Therapeutic Area
Table 4    Sources of Healthcare Data
Table 5    Global Real-World Evidence Solutions Market Restraints: Impact Analysis (2021-2028)
Table 6    RWE in Latin American Countries
Table 7    Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 8    Global Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 9    Global Real-World Evidence Solutions Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 10    Real-World Evidence Solutions Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 11    Global RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 12    RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 13    RWE Emr/Ehr/Clinical Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 14    RWE Claims & Billing Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 15    RWE Pharmacy Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 16    RWE Product/Disease Registries Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 17    Other RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 18    RWE Integrated Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 19    RWE Consulting & Analytics Market Size, by Country/Region, 2019–2028 (USD Million)
Table 20    Global Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 21    Global RWE Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2028 (USD Million)
Table 22    Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 23    Global RWE Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 24    Oncology: Drugs in the R&D Pipeline
Table 25    Global RWE Solutions Market Size for Oncology, by Country/Region, 2019–2028 (USD Million)
Table 26    Neurology: Drugs in the R&D Pipeline
Table 27    Global RWE Solutions Market Size for Neurology, by Country/Region, 2019–2028 (USD Million)
Table 28    Immunology: Drugs in the R&D Pipeline
Table 29    Global RWE Solutions Market Size for Immunology, by Country/Region, 2019–2028 (USD Million)
Table 30    Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 31    Cardiovascular Diseases: Drugs in the R&D Pipeline
Table 32    Global RWE Solutions Market Size for Cardiovascular Diseases, by Country/Region, 2019–2028 (USD Million)
Table 33    Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 34    Global RWE Solutions Market Size for Other Therapeutic Areas, by Country/Region, 2019–2028 (USD Million)
Table 35    Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 36    Global RWE Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2028 (USD Million)
Table 37    Global RWE Solutions Market Size for Other Applications,  by Country/Region, 2019–2028 (USD Million)
Table 38    Global RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 39   Global RWE Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2019–2028 (USD Million)
Table 40    Global RWE Solutions Market Size for Healthcare Payers, by Country/Region, 2019–2028 (USD Million)
Table 41    Global RWE Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2028 (USD Million)
Table 42    Global RWE Solutions Market Size for Other End Users,  by Country/Region, 2019–2028 (USD Million)
Table 43    Global Real-World Evidence Solutions Market, by Country/Region, 2019–2028 (USD Million)
Table 44    North America: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 45    North America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 46    North America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 47    North America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 48    North America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 49    North America: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 50    North America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 51    U.S.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 52    U.S.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 53    U.S.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 54    U.S.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 55    U.S.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 56    U.S.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 57    Number of Active Clinical Trials in Canada, by Condition, 2019
Table 58    Canada: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 59    Canada: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 60    Canada: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 61    Canada: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 62    Canada: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 63    Canada: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 64    Europe: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 65    Europe: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 66    Europe: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 67    Europe: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 68    Europe: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 69    Europe: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 70    Europe: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 71    U.K.: Conferences and Workshops on Real-World Evidence Solutions
Table 72    U.K.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 73    U.K.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 74    U.K.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 75    U.K.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 76    U.K.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 77    U.K.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 78    Conferences, Symposia, and Workshops in Germany
Table 79    Germany: Real-World Evidence Solutions Market Size, by Component,  2019–2028 (USD Million)
Table 80    Germany: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 81    Germany: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 82    Germany: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 83    Germany: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 84    Germany: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 85    France: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 86    France: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 87    France: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 88    France: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 89    France: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 90    France: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 91    Italy: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 92    Italy: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 93    Italy: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 94    Italy: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 95    Italy: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 96    Italy: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 97    Spain: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 98    Spain: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 99    Spain: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 100    Spain: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 101    Spain: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 102    Spain: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 103    RoE: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 104    RoE: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 105    RoE: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 106    RoE: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 107    RoE: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 108    RoE: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 109    Asia-Pacific: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 110    Asia-Pacific: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 111    Asia-Pacific: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 112    Asia-Pacific: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 113    Asia-Pacific: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 114    Asia-Pacific: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 115    Asia-Pacific: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 116    Japan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 117    Japan: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 118    Japan: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 119    Japan: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 120    Japan: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 121    Japan: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 122    Diversified Real-World Data Sources in China
Table 123    China: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 124    China: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 125    China: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 126    China: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 127    China: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 128    China: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 135    South Korea: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 141    RWE Sources Of Taiwan
Table 142    Taiwan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 148    Singapore: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 154    Estimated Number of New Cancer Cases From 2020 to 2030
Table 155    RoAPAC: Real-World Evidence Solutions Market Size, by Component,  2019–2028 (USD Million)
Table 156    RoAPAC: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 157    RoAPAC: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 158    RoAPAC: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 159    RoAPAC: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 160    RoAPAC: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 161    Latin America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 162    Latin America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 163    Latin America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 164    Latin America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 165    Latin America: RWE Market Size for Drug Development & Approvals,  by Therapeutic Area, 2019–2028 (USD Million)
Table 166    Latin America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 167    Middle East & Africa: Real-World Evidence Solutions Market Size,  by Component, 2019–2028 (USD Million)
Table 168    Middle East & Africa: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 169    Middle East & Africa: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 170    Middle East & Africa: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 171    Middle East & Africa: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 172    Middle East & Africa: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 173    Recent Developments, by Company, 2018–2021 

List of Figures

Figure 1    Key Stakeholders 
Figure 2    Research Process 
Figure 3    Key Secondary Sources 
Figure 4    Primary Research Techniques 
Figure 5    Key Executives Interviewed 
Figure 6    Breakdown of Primary Interviews (Supply-Side & Demand-Side) 
Figure 7    Market Size Estimation 
Figure 8    Global Real-World Evidence Solutions Market, by Component, 2021 Vs. 2028 (USD Million) 
Figure 9    Global Real-World Evidence Solutions Market, by Application, 2021 Vs. 2028 (USD Million) 
Figure 10    Global Real-World Evidence Solutions Market, by End User, 2021 Vs. 2028 (USD Million) 
Figure 11    Real-World Evidence Solutions Market, by Geography 
Figure 12    Market Dynamics 
Figure 13    Number of People With Chronic Conditions in the U.S. (2000–2030) 
Figure 14    Percentage of Personalized Medicines Approved (2015–2020) 
Figure 15    Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012–2020) 
Figure 16    Global Real-World Evidence Solutions Market Size, by Component, 2021–2028 (USD Million) 
Figure 17    U.S.: Number of E-Prescriptions, 2013–2020 (Billions) 
Figure 18    Global Real-World Evidence Solutions Market Size, by Application, 2021–2028(USD Million) 
Figure 19    Estimated Number of New Cancer Cases, by Region, 2020–2040 (in Millions) 
Figure 20    Global Real-World Evidence Solutions Market Size, by End User, 2021–2028 (USD Million) 
Figure 21    Pharmaceutical R&D Spending, 2012–2026 (USD Billion) 
Figure 22    Global Real-World Evidence Solutions Market, by Region, 2021–2028 (USD Million) 
Figure 23    North America: Real-World Evidence Solutions Market Snapshot 
Figure 24    Number of Novel Drug Approvals by CDER in a Year, 2010–2020 
Figure 25    Europe: Real-World Evidence Solutions Market Snapshot 
Figure 26    Pharmaceutical Industry R&D Expenditure in Germany, 2016–2019 (USD Million) 
Figure 27    France: Share of Population Aged 65 & Above, 2010–2020 
Figure 28    Italy: Share of Population Aged 65 Years and Above, 2015–2020 
Figure 29    Pharmaceutical R&D Expenditure in Spain, 2016–2019 (USD Million) 
Figure 30    Pharmaceutical R&D Expenditure in European Countries, 2016–2019 (USD Million) 
Figure 31    Asia-Pacific: Real-World Evidence Solutions Market Snapshot 
Figure 32    Number of People >65 Years of Age in Japan, 2000–2050 
Figure 33    Key Growth Strategies Adopted by Leading Players (2018–2021) 
Figure 34    Real-World Evidence Solutions: Competitive Benchmarking 
Figure 35    Market Share Analysis: Real-World Evidence Solutions Industry (2020) 
Figure 36    IQVIA Holdings Inc.: Financial Overview, 2020 
Figure 37    PPD, Inc.: Financial Overview, 2020 
Figure 38    ICON plc: Financial Overview, 2020 
Figure 39    SYNEOS HEALTH, INC.: financial overview (2020)
Figure 40    CLARIVATE PLC: financial overview (2020)
Figure 41    Medpace Holdings, Inc.: financial overview, 2020
Figure 42    IBM Corporation: Financial Overview, 2020 
Figure 43    UnitedHealth Group Incorporated: Financial Overview, 2020 
Figure 44    Oracle Corporation: Financial Overview, 2021 
Figure 45    Clinigen Group plc: Financial Overview, 2021 
Figure 46    Cognizant Technology Solutions Corporation: Financial Overview, 2020 
Figure 47    PerkinElmer, Inc.: Financial Overview, 2020 

  Request Sample

1.    Introduction
        1.1.    Market Definition 
        1.2.    Market Ecosystem 
        1.3.    Currency 

2.    Research Methodology 
        2.1.    Research Process 
        2.2.    Data Collection & Validation 
                  2.2.1.    Secondary Research 
                  2.2.2.    Primary Research 
        2.3.    Market Assessment 
                  2.3.1.    Market Size Estimation 
                               2.3.1.1.    Bottom-Up Approach 

3.    Executive Summary 

4.    Market Insights 
        4.1.    Market Overview 
        4.2.    Drivers 
                  4.2.1.    Growing Burden of Chronic Diseases 
                  4.2.2.    Rising Focus Towards Personalized Healthcare 
                  4.2.3.    Delays in Drug Development and the Subsequent Increase in Development Costs 
                  4.2.4.    Shift Towards Value-Based Care 
                  4.2.5.    Rapidly Growing Big Data in Healthcare 
        4.3.    Restraints 
                  4.3.1.    Reluctance to Rely on Real-World Studies 
        4.4.    Opportunities 
                  4.4.1.    Emerging Economies 
                  4.4.2.    Rising Focus on End-To-End RWE Services 
                  4.4.3.    Rising Adoption of Wearable Devices and Artificial Intelligence in RWE 
        4.5.    Challenges 
                  4.5.1.    Lack of Standardized Methodologies to Develop RWE 
        4.6.    Impact Assessment of COVID-19 
        4.7.    Key Market Trends 
                  4.7.1.    Growing Adoption of RWE in Drug Development and Commercialization 
                  4.7.2.    Rising Number of Consolidations 
                  4.7.3.    Improved Patient Outcomes and value Creation from real world Evidence 

5.    Regulatory Analysis – Real-World Evidence (RWE) Solutions Market 
        5.1.    Introduction 
        5.2.    North America 
        5.3.    Europe 
        5.4.    Asia-Pacific 
        5.5.    Rest of the World 

6.    Pricing Models (Emr/Genomic/Integrated Datasets) 
        6.1.    Introduction 
        6.2.    Pay Per Patient Record (Volume-Based Pricing) 
        6.3.    Pay Per Usage (Value-Based Pricing) 
        6.4.    Annual Subscription 

7.    Global Real-World Evidence Solutions Market, by Component 
        7.1.    Introduction 
        7.2.    Datasets 
                  7.2.1.   Disparate Datasets 
                               7.2.1.1.    EMR/EHR/Clinical Data 
                               7.2.1.2.    Claims & Billing Data 
                               7.2.1.3.    Pharmacy Data 
                               7.2.1.4.    Product/Disease Registries Data 
                               7.2.1.5.    Other Disparate Datasets 
                  7.2.2.    Integrated Datasets 
        7.3.    Consulting & Analytics 

8.    Global Real-World Evidence Solutions Market, by Application 
        8.1.    Introduction 
        8.2.    Market Access & Reimbursement/Coverage Decisions 
        8.3.    Drug Development & Approvals 
                  8.3.1.    Oncology 
                  8.3.2.    Neurology 
                  8.3.3.    Immunology 
                  8.3.4.    Cardiovascular Diseases 
                  8.3.5.    Other Therapeutic Areas 
        8.4.    Post Market Surveillance 
        8.5.     Medical Device Development & Approvals
        8.6.    Other Applications 

9.    Global Real-World Evidence Solutions Market, by End User 
        9.1.    Introduction 
        9.2.    Pharmaceutical, Biotechnology, and Medical Device Companies 
        9.3.    Healthcare Payers 
        9.4.    Healthcare Providers 
        9.5.    Other End Users 

10.    Global Real-World Evidence Solutions Market, by Geography 
         10.1.    Introduction 
         10.2.    North America 
                     10.2.1.    U.S. 
                     10.2.2.    Canada 
         10.3.    Europe 
                     10.3.1.    U.K. 
                     10.3.2.    Germany 
                     10.3.3.    France 
                     10.3.4.    Italy
                     10.3.5.    Spain
                     10.3.6.    Rest of Europe
         10.4.    Asia-Pacific
                     10.4.1.    Japan 
                     10.4.2.    China 
                     10.4.3.    India 
                     10.4.4.    South Korea 
                     10.4.5.    Taiwan 
                     10.4.6.    Singapore 
                     10.4.7.    Rest of Asia-Pacific 
         10.5.    Latin America 
         10.6.    Middle East & Africa 

11.    Competitive Landscape 
         11.1.    Introduction 
         11.2.    Key Growth Strategies 
         11.3.    Competitive Benchmarking 
         11.4.    Market Share Analysis (2020) 
                     11.4.1.    IQVIA Holdings, Inc. (U.S.) 
                     11.4.2.    Icon Plc (Ireland) 
                     11.4.3.    PPD, Inc. 

12.    Company Profiles 
         12.1.    IQVIA Holdings Inc. 
                     12.1.1.    Business Overview 
                     12.1.2.    Financial Overview 
                     12.1.3.    Product Portfolio 
                     12.1.4.    Strategic Developments 
         12.2.    PPD, Inc. 
                     12.2.1.    Business Overview 
                     12.2.2.    Financial Overview 
                     12.2.3.    Product Portfolio 
                     12.2.4.    Strategic Developments 
         12.3.    ICON plc 
                     12.3.1.    Business Overview 
                     12.3.2.    Financial Overview 
                     12.3.3.    Product Portfolio 
                     12.3.4.    Strategic Developments 
         12.4.    SYNEOS HEALTH, INC.
                     12.4.1.    Business Overview 
                     12.4.2.    Financial Overview 
                     12.4.3.    Product Portfolio 
                     12.4.4.    Strategic Developments 
         12.5.    CLARIVATE PLC
                     12.5.1.    Business Overview 
                     12.5.2.    Financial Overview 
                     12.5.3.    Product Portfolio 
         12.6.    Medpace Holdings Inc.
                     12.6.1.    Business Overview 
                     12.6.2.    Financial Overview 
                     12.6.3.    Product Portfolio 
         12.7.    Symphony Innovation, LLC
                     12.7.1.    Business Overview 
                     12.7.2.    Product Portfolio 
                     12.7.3.    Strategic Developments 
         12.8.    PAREXEL International Corporation 
                     12.8.1.    Business Overview 
                     12.8.2.    Product Portfolio 
                     12.8.3.    Strategic Developments 
         12.9.    IBM Corporation 
                     12.9.1.    Business Overview
                     12.9.2.    Financial Overview 
                     12.9.3.    Product Portfolio 
                     12.9.4.    Strategic Developments 
         12.10.  UnitedHealth Group Incorporated 
                     12.10.1.    Business Overview 
                     12.10.2.    Financial Overview 
                     12.10.3.    Product Portfolio 
         12.11.  Flatiron Health 
                     12.11.1.    Business Overview 
                     12.11.2.    Product Portfolio 
                     12.11.3.    Strategic Developments 
         12.12.  Oracle Corporation 
                     12.12.1.    Business Overview 
                     12.12.2.    Financial Overview 
                     12.12.3.    Product Portfolio 
         12.13.  SAS Institute, Inc. 
                     12.13.1.    Business Overview 
                     12.13.2.    Product Portfolio 
                     12.13.2.    Strategic Developments 
         12.14.  Clinigen Group plc 
                     12.14.1.    Business Overview 
                     12.14.2.    Financial Overview 
                     12.14.3.    Product Portfolio 
         12.15.  Cognizant Technology Solutions Corporation 
                     12.15.1.    Business Overview 
                     12.15.2.    Financial Overview 
                     12.15.3.    Product Portfolio 
         12.16.  PerkinElmer, Inc. 
                     12.16.1.    Business Overview 
                     12.16.2.    Financial Overview 
                     12.16.3.    Product Portfolio 

13.    Appendix 
         13.1.    Questionnaire 
         13.2.    Available Customization 

List of Tables

Table 1    Global Real-World Evidencesolutions Market Drivers: Impact Analysis (2021-2028)
Table 2    Number of Persons Aged 65 Years or Over, by Region, (2019 Vs. 2050)
Table 3    Total Per-Study Cost (In USD Million), by Phase and Therapeutic Area
Table 4    Sources of Healthcare Data
Table 5    Global Real-World Evidence Solutions Market Restraints: Impact Analysis (2021-2028)
Table 6    RWE in Latin American Countries
Table 7    Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 8    Global Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 9    Global Real-World Evidence Solutions Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 10    Real-World Evidence Solutions Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 11    Global RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 12    RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 13    RWE Emr/Ehr/Clinical Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 14    RWE Claims & Billing Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 15    RWE Pharmacy Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 16    RWE Product/Disease Registries Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 17    Other RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 18    RWE Integrated Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 19    RWE Consulting & Analytics Market Size, by Country/Region, 2019–2028 (USD Million)
Table 20    Global Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 21    Global RWE Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2028 (USD Million)
Table 22    Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 23    Global RWE Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 24    Oncology: Drugs in the R&D Pipeline
Table 25    Global RWE Solutions Market Size for Oncology, by Country/Region, 2019–2028 (USD Million)
Table 26    Neurology: Drugs in the R&D Pipeline
Table 27    Global RWE Solutions Market Size for Neurology, by Country/Region, 2019–2028 (USD Million)
Table 28    Immunology: Drugs in the R&D Pipeline
Table 29    Global RWE Solutions Market Size for Immunology, by Country/Region, 2019–2028 (USD Million)
Table 30    Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 31    Cardiovascular Diseases: Drugs in the R&D Pipeline
Table 32    Global RWE Solutions Market Size for Cardiovascular Diseases, by Country/Region, 2019–2028 (USD Million)
Table 33    Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 34    Global RWE Solutions Market Size for Other Therapeutic Areas, by Country/Region, 2019–2028 (USD Million)
Table 35    Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 36    Global RWE Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2028 (USD Million)
Table 37    Global RWE Solutions Market Size for Other Applications,  by Country/Region, 2019–2028 (USD Million)
Table 38    Global RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 39   Global RWE Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2019–2028 (USD Million)
Table 40    Global RWE Solutions Market Size for Healthcare Payers, by Country/Region, 2019–2028 (USD Million)
Table 41    Global RWE Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2028 (USD Million)
Table 42    Global RWE Solutions Market Size for Other End Users,  by Country/Region, 2019–2028 (USD Million)
Table 43    Global Real-World Evidence Solutions Market, by Country/Region, 2019–2028 (USD Million)
Table 44    North America: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 45    North America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 46    North America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 47    North America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 48    North America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 49    North America: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 50    North America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 51    U.S.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 52    U.S.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 53    U.S.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 54    U.S.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 55    U.S.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 56    U.S.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 57    Number of Active Clinical Trials in Canada, by Condition, 2019
Table 58    Canada: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 59    Canada: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 60    Canada: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 61    Canada: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 62    Canada: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 63    Canada: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 64    Europe: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 65    Europe: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 66    Europe: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 67    Europe: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 68    Europe: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 69    Europe: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 70    Europe: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 71    U.K.: Conferences and Workshops on Real-World Evidence Solutions
Table 72    U.K.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 73    U.K.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 74    U.K.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 75    U.K.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 76    U.K.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 77    U.K.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 78    Conferences, Symposia, and Workshops in Germany
Table 79    Germany: Real-World Evidence Solutions Market Size, by Component,  2019–2028 (USD Million)
Table 80    Germany: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 81    Germany: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 82    Germany: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 83    Germany: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 84    Germany: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 85    France: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 86    France: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 87    France: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 88    France: Real-World Evidence Solutions Market Size, by Application,  2019–2028 (USD Million)
Table 89    France: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 90    France: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 91    Italy: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 92    Italy: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 93    Italy: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 94    Italy: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 95    Italy: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 96    Italy: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 97    Spain: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 98    Spain: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 99    Spain: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 100    Spain: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 101    Spain: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 102    Spain: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 103    RoE: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 104    RoE: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 105    RoE: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 106    RoE: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 107    RoE: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 108    RoE: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 109    Asia-Pacific: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 110    Asia-Pacific: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 111    Asia-Pacific: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 112    Asia-Pacific: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 113    Asia-Pacific: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 114    Asia-Pacific: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 115    Asia-Pacific: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 116    Japan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 117    Japan: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 118    Japan: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 119    Japan: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 120    Japan: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 121    Japan: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 122    Diversified Real-World Data Sources in China
Table 123    China: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 124    China: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 125    China: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 126    China: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 127    China: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 128    China: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 135    South Korea: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 141    RWE Sources Of Taiwan
Table 142    Taiwan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 148    Singapore: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 154    Estimated Number of New Cancer Cases From 2020 to 2030
Table 155    RoAPAC: Real-World Evidence Solutions Market Size, by Component,  2019–2028 (USD Million)
Table 156    RoAPAC: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 157    RoAPAC: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 158    RoAPAC: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 159    RoAPAC: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 160    RoAPAC: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 161    Latin America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 162    Latin America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 163    Latin America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 164    Latin America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 165    Latin America: RWE Market Size for Drug Development & Approvals,  by Therapeutic Area, 2019–2028 (USD Million)
Table 166    Latin America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 167    Middle East & Africa: Real-World Evidence Solutions Market Size,  by Component, 2019–2028 (USD Million)
Table 168    Middle East & Africa: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 169    Middle East & Africa: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 170    Middle East & Africa: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 171    Middle East & Africa: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 172    Middle East & Africa: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 173    Recent Developments, by Company, 2018–2021 

List of Figures

Figure 1    Key Stakeholders 
Figure 2    Research Process 
Figure 3    Key Secondary Sources 
Figure 4    Primary Research Techniques 
Figure 5    Key Executives Interviewed 
Figure 6    Breakdown of Primary Interviews (Supply-Side & Demand-Side) 
Figure 7    Market Size Estimation 
Figure 8    Global Real-World Evidence Solutions Market, by Component, 2021 Vs. 2028 (USD Million) 
Figure 9    Global Real-World Evidence Solutions Market, by Application, 2021 Vs. 2028 (USD Million) 
Figure 10    Global Real-World Evidence Solutions Market, by End User, 2021 Vs. 2028 (USD Million) 
Figure 11    Real-World Evidence Solutions Market, by Geography 
Figure 12    Market Dynamics 
Figure 13    Number of People With Chronic Conditions in the U.S. (2000–2030) 
Figure 14    Percentage of Personalized Medicines Approved (2015–2020) 
Figure 15    Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012–2020) 
Figure 16    Global Real-World Evidence Solutions Market Size, by Component, 2021–2028 (USD Million) 
Figure 17    U.S.: Number of E-Prescriptions, 2013–2020 (Billions) 
Figure 18    Global Real-World Evidence Solutions Market Size, by Application, 2021–2028(USD Million) 
Figure 19    Estimated Number of New Cancer Cases, by Region, 2020–2040 (in Millions) 
Figure 20    Global Real-World Evidence Solutions Market Size, by End User, 2021–2028 (USD Million) 
Figure 21    Pharmaceutical R&D Spending, 2012–2026 (USD Billion) 
Figure 22    Global Real-World Evidence Solutions Market, by Region, 2021–2028 (USD Million) 
Figure 23    North America: Real-World Evidence Solutions Market Snapshot 
Figure 24    Number of Novel Drug Approvals by CDER in a Year, 2010–2020 
Figure 25    Europe: Real-World Evidence Solutions Market Snapshot 
Figure 26    Pharmaceutical Industry R&D Expenditure in Germany, 2016–2019 (USD Million) 
Figure 27    France: Share of Population Aged 65 & Above, 2010–2020 
Figure 28    Italy: Share of Population Aged 65 Years and Above, 2015–2020 
Figure 29    Pharmaceutical R&D Expenditure in Spain, 2016–2019 (USD Million) 
Figure 30    Pharmaceutical R&D Expenditure in European Countries, 2016–2019 (USD Million) 
Figure 31    Asia-Pacific: Real-World Evidence Solutions Market Snapshot 
Figure 32    Number of People >65 Years of Age in Japan, 2000–2050 
Figure 33    Key Growth Strategies Adopted by Leading Players (2018–2021) 
Figure 34    Real-World Evidence Solutions: Competitive Benchmarking 
Figure 35    Market Share Analysis: Real-World Evidence Solutions Industry (2020) 
Figure 36    IQVIA Holdings Inc.: Financial Overview, 2020 
Figure 37    PPD, Inc.: Financial Overview, 2020 
Figure 38    ICON plc: Financial Overview, 2020 
Figure 39    SYNEOS HEALTH, INC.: financial overview (2020)
Figure 40    CLARIVATE PLC: financial overview (2020)
Figure 41    Medpace Holdings, Inc.: financial overview, 2020
Figure 42    IBM Corporation: Financial Overview, 2020 
Figure 43    UnitedHealth Group Incorporated: Financial Overview, 2020 
Figure 44    Oracle Corporation: Financial Overview, 2021 
Figure 45    Clinigen Group plc: Financial Overview, 2021 
Figure 46    Cognizant Technology Solutions Corporation: Financial Overview, 2020 
Figure 47    PerkinElmer, Inc.: Financial Overview, 2020 

  Request Sample
Related Research